Drugs.com

APRIL 30, 2025

2024, GlaxoSmithKline withdrew Flovent from the market. WEDNESDAY, April 30, 2025 More children stopped using steroid inhalers to control their asthma after a manufacturer discontinued a popular inhaler, a new study says.In The inhaler was c.

Marketing 242

Marketing Production 242

Drugs.com

OCTOBER 10, 2023

They are marketed with. MONDAY, Oct. 9, 2023 -- Flavoring added to small, cheap cigars is making these the second-most popular tobacco product among youth, a new report shows. The report comes as federal regulators prepare to bar flavored cigars.

Marketing 264

Marketing Regulations Production 264

BioPharma Drive: Drug Pricing

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 246

BioPharma Drive: Drug Pricing

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 319

Marketing 319

Drugs.com

JULY 19, 2024

FRIDAY, July 19, 2024 -- The U.S. Food and Drug Administration on Thursday authorized the sale of the country's best-selling e-cigarette.The agency's decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse.

Marketing 264

Marketing FDA Production Drugs 264

BioPharma Drive: Drug Pricing

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Marketing 275

Marketing Drugs 275

Perficient: Drug Development

JULY 8, 2025

In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential.

52

52

Drugs.com

FEBRUARY 21, 2024

WEDNESDAY, Feb. 21, 2024 -- A popular asthma inhaler was discontinued on Jan. 1, and the business move has left families scrambling to find a replacement for their kids.Flovent was one of the most commonly prescribed drugs for childhood asthma, but.

Marketing 293

Marketing Drugs 293

BioPharma Drive: Drug Pricing

JUNE 18, 2025

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.

FDA Approval 294

FDA Approval FDA Marketing Drugs 294

BioPharma Drive: Drug Pricing

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 285

Trials Marketing Drugs 285

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle.

Marketing 98

Marketing International Drugs 98

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 256

Marketing Drugs 256

Drug Patent Watch

JUNE 16, 2025

A new analysis from Drug Patent Watch reveals the hidden timeline behind generic drug entry, and the market dynamics that will be reshaped in its wake. Read the full report: [link] #pharmaceuticals #patentexpiration #genericdrugs"

Marketing 68

Marketing Drugs Pharmaceuticals 68

Perficient: Drug Development

JULY 1, 2025

The New Expectations in Medical Device Marketing Today’s providers and patients expect more than just innovative products—they want personalized, value-driven experiences. Why Salesforce Marketing Cloud? Let’s modernize your marketing, elevate your engagement strategy, and make every campaign smarter.

Marketing 52

Marketing Compliance Production Science 52

The Pharma Data

JULY 3, 2025

Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. and marks Sunshine Biopharma’s entry into the rapidly expanding global biologics and biosimilars market. The global market for NEULASTA® and its biosimilars is substantial. In 2024, it was valued at approximately $4.5

Marketing 52

Marketing Biosimilars Pharmaceutical Companies Pharmaceuticals 52

BioPharma Drive: Drug Pricing

MARCH 24, 2025

Understanding private sector breakthroughs, acquisitions and funding is critical in a volatile market.

Marketing 162

Marketing 162

Drug Patent Watch

APRIL 10, 2025

The team at Drug Patent Watch has done an incredible job of breaking down the key considerations for turning scientific discoveries into market power. "Just spent the morning digging into the world of pharmaceuticals and I'm blown away by the complexities of drafting effective drug patent applications.

Science 76

Science Marketing Drugs Pharmaceuticals 76

Drug Channels

JUNE 18, 2025

Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Marketing Drugs 75

Crucial Data Solutions

JUNE 10, 2025

The Post-Market Shift: From Sites to Data Streams Phase IV trials used to mean tracking long-term outcomes by continuing to. The post Modern Post-Market Trials Will Be Driven by RWD – Is Your EDC Ready? appeared first on Crucial Data Solutions.

Trials 59

Trials Marketing Clinical Trials 59

BioPharma Drive: Drug Pricing

OCTOBER 29, 2024

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Vaccine 173

Vaccine Marketing 173

BioPharma Drive: Drug Pricing

APRIL 7, 2025

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Marketing 147

Marketing Drugs 147

BioPharma Drive: Drug Pricing

APRIL 29, 2025

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination that Wegovy is no longer in shortage.

Marketing 162

Marketing FDA 162

BioPharma Drive: Drug Pricing

JUNE 26, 2025

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

Drug Development 173

Drug Development Production Marketing Drugs 173

Drugs.com

FEBRUARY 21, 2025

FRIDAY, Feb. 21, 2025 -- New York Attorney General Letitia James filed a major lawsuit yesterday, accusing 13 e-cigarette companies of illegally selling flavored vapes and targeting young kids through deceptive marketing.The 192-page complaint.

Marketing 147

Marketing 147

BioPharma Drive: Drug Pricing

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 328

FDA Marketing Drugs 328

Drug Patent Watch

JULY 2, 2025

"The Dragon's Rise: How China's Pharmaceutical Industry is Igniting a Global Revolution In a seismic shift for the global healthcare landscape, China's pharmaceutical industry is roaring to life, with exports projected to reach $143 billion by 2025. But what's behind this unstoppable growth, and what does it mean for the future of medicine?

Pharmaceuticals 62

Pharmaceuticals Marketing 62

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 331

Marketing 331

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 328

Drugs Marketing 328

BioPharma Drive: Drug Pricing

JULY 11, 2024

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Marketing 321

Marketing Drugs 321

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 317

Drug Trials Trials Treatment Marketing 317

BioPharma Drive: Drug Pricing

NOVEMBER 22, 2024

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

FDA 312

FDA Marketing Drugs 312

BioPharma Drive: Drug Pricing

AUGUST 2, 2024

Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.

Therapies 312

Therapies FDA Marketing 312

BioPharma Drive: Drug Pricing

OCTOBER 13, 2023

Sales of Pfizer's antiviral Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral has been delayed.

Production 344

Production Marketing 344

BioPharma Drive: Drug Pricing

NOVEMBER 14, 2024

But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market. A key regulatory committee sided against the drug this summer.

Regulations 312

Regulations Drugs Marketing 312

BioPharma Drive: Drug Pricing

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Marketing 344

Marketing Drugs 344

BioPharma Drive: Drug Pricing

AUGUST 19, 2024

The race to corner this large projected market is already getting tight. A new wave of antipsychotics could improve patient adherence.

Marketing 298

Marketing Drugs 298

BioPharma Drive: Drug Pricing

AUGUST 5, 2024

For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical.

Marketing 264

Marketing Disease 264